Alpha 2.0
Login Register
» Articles » PMID: 21897714

Cross Sensitivity Between Ciprofloxacin and Levofloxacin for an Immediate Hypersensitivity Reaction

Overview
Journal J Pharmacol Pharmacother
Specialty Pharmacology
Date 2011 Sep 8
PMID 21897714
Citations 8
Authors
Ashish P Anovadiya
Manish J Barvaliya
Tejas K Patel
C B Tripathi
Affiliations
Soon will be listed here.
Abstract

Seven years old male child (24 kg weight) diagnosed as a case of sub acute appendicitis treated with ciprofloxacin, immediately developed multiple erythmatous papules. Reaction subsided after withholding ciprofloxacin and treatment with dexamethasone and chlorpheneramine maleate. It was developed again when treated with levofloxacin and subsided after withdrawal. IgE binding at 7(th) position of core structure of fluoroquinolones likely to be the mechanism. As all the fluoroquinolones have similar core structure, hypersensitivity to one may have cross sensitivity to other fluoroquinolones. It is advisable to avoid other fluoroquinolones and switch over to other group of antibiotics when hypersensitivity to one occurs.

Citing Articles

Ciprofloxacin-Induced Anaphylactic Reaction Followed by Negative Provocation Test in Response to Levofloxacin: A Case Report.

Kurtov M, Kilic P, Ikic L, Kurtov K, Dorcic G, Vodanovic M Medicina (Kaunas). 2023; 59(10).

PMID: 37893502 PMC: 10608669. DOI: 10.3390/medicina59101784.

Immediate Hypersensitivity to Fluoroquinolones: 
A Cohort Assessing Cross-Reactivity.

Azimi S, Mainella V, Jeffres M Open Forum Infect Dis. 2022; 9(4):ofac106.

PMID: 35355888 PMC: 8962755. DOI: 10.1093/ofid/ofac106.

Trends in the Design of Intensity-Based Optical Fiber Biosensors (2010-2020).

De Acha N, Socorro-Leranoz A, Elosua C, Matias I Biosensors (Basel). 2021; 11(6).

PMID: 34203715 PMC: 8232210. DOI: 10.3390/bios11060197.

Quinolone Allergy.

McGee E, Samuel E, Boronea B, Dillard N, Milby M, Lewis S Pharmacy (Basel). 2019; 7(3).

PMID: 31330937 PMC: 6789783. DOI: 10.3390/pharmacy7030097.

Immediate type hypersensitivity and late phase reaction occurred consecutively in a patient receiving ethambutol and levofloxacin.

Kato Y, Sato Y, Nakasu M, Tsuboi R Allergy Asthma Clin Immunol. 2018; 14:13.

PMID: 29619062 PMC: 5881183. DOI: 10.1186/s13223-018-0237-x.

References
1.
Naranjo C, Busto U, Sellers E, Sandor P, Ruiz I, Roberts E . A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30(2):239-45. DOI: 10.1038/clpt.1981.154. View
2.
Gonzalez I, Lobera T, Blasco A, Del Pozo M . Immediate hypersensitivity to quinolones: moxifloxacin cross-reactivity. J Investig Allergol Clin Immunol. 2005; 15(2):146-9. View
3.
Hartwig S, Siegel J, SCHNEIDER P . Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm. 1992; 49(9):2229-32. View
4.
Schumock G, Thornton J . Focusing on the preventability of adverse drug reactions. Hosp Pharm. 1992; 27(6):538. View
5.
Venturini Diaz M, Lobera Labairu T, Del Pozo Gil M, Blasco Sarramian A, Gonzalez Mahave I . In vivo diagnostic tests in adverse reactions to quinolones. J Investig Allergol Clin Immunol. 2007; 17(6):393-8. View